Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.54 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.54 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080268 | 0.90 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL10028305 | 0.87 | OPRL1 (0.46) | OPRM1OPRD1OPRK1OPRL1POLB | |
| SCHEMBL28299186 | 0.85 | OPRM1 (0.58) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL21078139 | 0.84 | OPRM1 (0.60) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL23384021 | 0.83 | OPRM1 (0.67) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL19226368 | 0.83 | OPRM1 (0.58) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL10319703 | 0.81 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL12317609 | 0.81 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1MEN1 | |
| SCHEMBL14438093 | 0.80 | ALDH1A1 (0.50) | MEN1ALDH1A1KMT2ACCR1DRD2 | |
| SCHEMBL10389866 | 0.80 | OPRM1 (0.67) | OPRM1OPRD1OPRK1OPRL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021076886-A1 | 3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20180000807-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170258777-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| WO-2015032286-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| US-4954511-A | ALLEVIATING PAIN, TREATING DEPRESSION, CONVULSIONS AND HYPERTENSION | HOECHST-ROUSSELL PHARMACEUTICALS INC. (US) | 1990-09-04 | — | — | US | disclosed |
| US-4914204-A | ANALGESICS, ANTIDEPRESSANTS, ANTICONVULSANTS, HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0333027-A1 | 4-Pentafluorophenoxypiperidines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000807-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | OPRM1 57/4885OPRD1 62/4885OPRK1 48/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | OPRM1 309/4885OPRD1 462/4885OPRK1 244/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | OPRM1 57/4885OPRD1 62/4885OPRK1 48/4885 |
| US-20170258777-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | OPRM1 57/4885OPRD1 62/4885OPRK1 48/4885 |
| US-20160081995-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | OPRM1 57/4885OPRD1 62/4885OPRK1 48/4885 |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | OPRM1 57/4885OPRD1 62/4885OPRK1 48/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | OPRM1 1787/4885OPRD1 1381/4885OPRK1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.